Mark Hopman Sells 5,327 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 5,327 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total transaction of $101,798.97. Following the completion of the transaction, the insider directly owned 124,027 shares in the company, valued at $2,370,155.97. The trade was a 4.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Mark Hopman also recently made the following trade(s):

• On Wednesday, June 24th, Mark Hopman sold 1,258 shares of Beta Bionics stock. The stock was sold at an average price of $15.01, for a total transaction of $18,882.58.

Beta Bionics Stock Performance

Shares of BBNX opened at $19.42 on Friday. Beta Bionics, Inc. has a 52 week low of $8.80 and a 52 week high of $32.71. The firm has a market cap of $873.71 million, a P/E ratio of -11.77 and a beta of 3.37. The firm’s 50-day simple moving average is $17.17 and its 200 day simple moving average is $13.65.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The firm had revenue of $32.01 million for the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. As a group, equities analysts forecast that Beta Bionics, Inc. will post -2.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on BBNX shares. Weiss Ratings upgraded Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. The Goldman Sachs Group increased their price objective on Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Bank of America dropped their target price on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a report on Monday, May 18th. Truist Financial boosted their target price on shares of Beta Bionics from $18.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Finally, UBS Group started coverage on shares of Beta Bionics in a research note on Tuesday, July 28th. They issued a “buy” rating and a $22.00 price target on the stock. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Beta Bionics currently has a consensus rating of “Moderate Buy” and an average target price of $20.10.

More Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Analyst sentiment remains favorable overall, with seven Buy ratings, four Holds and one Sell, producing a “Moderate Buy” consensus and an average price target of $20.10. Recent institutional purchases, including a new position by Bank of America valued at approximately $8.6 million, also provide some support. Beta Bionics insider trading and analyst coverage
• Neutral Sentiment: Several Beta Bionics insiders—including CFO Stephen Feider, Steven Russell, Mike Mensinger and Mark Hopman—sold shares at approximately $19.11 each. The transactions collectively involved about 20,600 shares, but the filings state the sales were made to cover tax-withholding obligations tied to vested equity awards, reducing their significance as a discretionary bearish signal. Beta Bionics insider sales
• Negative Sentiment: Schall, Brown & Schwartz LLP announced that it has filed a class-action lawsuit against Beta Bionics and is seeking investors to serve as lead plaintiffs. The litigation introduces potential legal costs, reputational risk and uncertainty regarding the company’s disclosures or conduct, creating the most significant near-term pressure on BBNX. The allegations have not been adjudicated. BBNX investor alert and class-action lawsuit

Institutional Investors Weigh In On Beta Bionics

Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new position in Beta Bionics in the 2nd quarter valued at about $52,340,000. Vanguard Group Inc. lifted its holdings in shares of Beta Bionics by 213.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock worth $44,036,000 after acquiring an additional 1,509,217 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Beta Bionics during the 4th quarter worth approximately $40,437,000. Eversept Partners LP boosted its position in shares of Beta Bionics by 108.6% during the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock worth $14,177,000 after acquiring an additional 736,576 shares in the last quarter. Finally, 12 West Capital Management LP acquired a new stake in shares of Beta Bionics during the 4th quarter worth approximately $17,520,000.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.